Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has been given an average rating of “Hold” by the twenty-seven analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $14.76.
TEVA has been the topic of several research analyst reports. Morgan Stanley set a $70.00 target price on shares of Edison International and gave the stock a “hold” rating in a research report on Monday, July 15th. Royal Bank of Canada set a $60.00 price target on shares of Masonite International and gave the company a “buy” rating in a report on Friday, May 3rd. Argus started coverage on shares of Ameriprise Financial in a report on Friday, July 5th. They issued a “buy” rating on the stock. Wolfe Research started coverage on shares of Teva Pharmaceutical Industries in a report on Friday. They issued a “peer perform” rating on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price target (up previously from $116.00) on shares of Zoetis in a report on Wednesday, June 12th.
In other news, VP Notaristefani Carlo De sold 16,070 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares in the company, valued at $567,105.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sol J. Barer acquired 111,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were purchased at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the purchase, the director now directly owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The disclosure for this purchase can be found here. Company insiders own 0.49% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its position in shares of Teva Pharmaceutical Industries by 4.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after buying an additional 767 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Teva Pharmaceutical Industries by 3.6% during the first quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock worth $384,000 after buying an additional 856 shares in the last quarter. Hancock Whitney Corp grew its position in shares of Teva Pharmaceutical Industries by 7.8% during the fourth quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock worth $186,000 after buying an additional 868 shares in the last quarter. Lindbrook Capital LLC grew its position in shares of Teva Pharmaceutical Industries by 61.2% during the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after buying an additional 945 shares in the last quarter. Finally, Wedbush Securities Inc. grew its position in shares of Teva Pharmaceutical Industries by 3.7% during the first quarter. Wedbush Securities Inc. now owns 28,385 shares of the company’s stock worth $445,000 after buying an additional 1,015 shares in the last quarter. Institutional investors own 65.05% of the company’s stock.
Shares of TEVA traded up $0.08 during mid-day trading on Friday, hitting $7.91. The company had a trading volume of 17,323,327 shares, compared to its average volume of 17,668,984. The business has a 50-day moving average of $8.87. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66. Teva Pharmaceutical Industries has a 1-year low of $7.66 and a 1-year high of $25.96. The company has a market cap of $7.96 billion, a PE ratio of 2.83, a PEG ratio of 0.94 and a beta of 1.62.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion for the quarter, compared to analysts’ expectations of $4.38 billion. During the same period last year, the company earned $0.94 earnings per share. The company’s quarterly revenue was down 15.2% on a year-over-year basis. Research analysts forecast that Teva Pharmaceutical Industries will post 2.27 earnings per share for the current year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: Strangles
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.